These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25479232)

  • 1. A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model.
    Rahim S; Minas T; Hong SH; Justvig S; Çelik H; Kont YS; Han J; Kallarakal AT; Kong Y; Rudek MA; Brown ML; Kallakury B; Toretsky JA; Üren A
    PLoS One; 2014; 9(12):e114260. PubMed ID: 25479232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.
    Rahim S; Beauchamp EM; Kong Y; Brown ML; Toretsky JA; Üren A
    PLoS One; 2011 Apr; 6(4):e19343. PubMed ID: 21559405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
    Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
    Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.
    Paulo P; Ribeiro FR; Santos J; Mesquita D; Almeida M; Barros-Silva JD; Itkonen H; Henrique R; Jerónimo C; Sveen A; Mills IG; Skotheim RI; Lothe RA; Teixeira MR
    Neoplasia; 2012 Jul; 14(7):600-11. PubMed ID: 22904677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.
    Yu L; Wu X; Chen M; Huang H; He Y; Wang H; Li D; Du Z; Zhang K; Goodin S; Zheng X
    Int J Med Sci; 2017; 14(4):356-366. PubMed ID: 28553168
    [No Abstract]   [Full Text] [Related]  

  • 7. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene.
    Im YH; Kim HT; Lee C; Poulin D; Welford S; Sorensen PH; Denny CT; Kim SJ
    Cancer Res; 2000 Mar; 60(6):1536-40. PubMed ID: 10749119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279.
    Winters B; Brown L; Coleman I; Nguyen H; Minas TZ; Kollath L; Vasioukhin V; Nelson P; Corey E; Üren A; Morrissey C
    Anticancer Res; 2017 Jul; 37(7):3385-3396. PubMed ID: 28668826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
    Tomlins SA; Rhodes DR; Perner S; Dhanasekaran SM; Mehra R; Sun XW; Varambally S; Cao X; Tchinda J; Kuefer R; Lee C; Montie JE; Shah RB; Pienta KJ; Rubin MA; Chinnaiyan AM
    Science; 2005 Oct; 310(5748):644-8. PubMed ID: 16254181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients.
    Baena E; Shao Z; Linn DE; Glass K; Hamblen MJ; Fujiwara Y; Kim J; Nguyen M; Zhang X; Godinho FJ; Bronson RT; Mucci LA; Loda M; Yuan GC; Orkin SH; Li Z
    Genes Dev; 2013 Mar; 27(6):683-98. PubMed ID: 23512661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
    Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
    Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the TMPRSS2-ERG gene fusion in prostate cancer.
    Tomlins SA; Laxman B; Varambally S; Cao X; Yu J; Helgeson BE; Cao Q; Prensner JR; Rubin MA; Shah RB; Mehra R; Chinnaiyan AM
    Neoplasia; 2008 Feb; 10(2):177-88. PubMed ID: 18283340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts.
    Mesquita D; Barros-Silva JD; Santos J; Skotheim RI; Lothe RA; Paulo P; Teixeira MR
    Oncotarget; 2015 Mar; 6(7):5217-36. PubMed ID: 25595908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
    Winnes M; Lissbrant E; Damber JE; Stenman G
    Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.
    Butler MS; Roshan-Moniri M; Hsing M; Lau D; Kim A; Yen P; Mroczek M; Nouri M; Lien S; Axerio-Cilies P; Dalal K; Yau C; Ghaidi F; Guo Y; Yamazaki T; Lawn S; Gleave ME; Gregory-Evans CY; McIntosh LP; Cox ME; Rennie PS; Cherkasov A
    Oncotarget; 2017 Jun; 8(26):42438-42454. PubMed ID: 28465491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.
    Lunardi A; Varmeh S; Chen M; Taulli R; Guarnerio J; Ala U; Seitzer N; Ishikawa T; Carver BS; Hobbs RM; Quarantotti V; Ng C; Berger AH; Nardella C; Poliseno L; Montironi R; Castillo-Martin M; Cordon-Cardo C; Signoretti S; Pandolfi PP
    Cancer Discov; 2015 May; 5(5):550-63. PubMed ID: 25653093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ETS variant 1 regulates matrix metalloproteinase-7 transcription in LNCaP prostate cancer cells.
    Shin S; Oh S; An S; Janknecht R
    Oncol Rep; 2013 Jan; 29(1):306-14. PubMed ID: 23076342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA interference targeting PSCA suppresses primary tumor growth and metastasis formation of human prostate cancer xenografts in SCID mice.
    Zhao Z; He J; Kang R; Zhao S; Liu L; Li F
    Prostate; 2016 Feb; 76(2):184-98. PubMed ID: 26477693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.
    Dong J; Xiao L; Sheng L; Xu J; Sun ZQ
    Asian Pac J Cancer Prev; 2014; 15(7):3099-103. PubMed ID: 24815454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer.
    Barros-Silva JD; Paulo P; Bakken AC; Cerveira N; Løvf M; Henrique R; Jerónimo C; Lothe RA; Skotheim RI; Teixeira MR
    Neoplasia; 2013 Jul; 15(7):720-6. PubMed ID: 23814484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.